Animol Discovery, Inc. Announces Series B Financing of $34.0 million to Advance Its Pipeline of Novel Veterinary Pharmaceuticals
Animol Discovery, Inc., a pioneer in veterinary pharmaceutical discovery, today announced it has raised $34.0 million in Series B financing. The investment was led by Novalis Lifesciences, with participation from Finistere Ventures and existing investor Anterra Capital. The proceeds allow the company to expand and advance its pipeline of novel active pharmaceutical ingredients through clinical development and further enhance its cutting-edge drug discovery platform.
The $40Bn animal health industry continues to demand novel medicines to treat infectious and chronic diseases in companion and production animals. Recent successes, such as Apoquel™ from Zoetis and Nexguard™ from Boehringer Ingelheim, demonstrate the potential to build towards blockbuster franchises in the sector with novel pharmaceutical products.
“Pet parents and livestock farmers continue to demand novel veterinary pharmaceuticals that can protect animals against diseases and improve quality of life,” said Andrew Plant PhD, chief executive officer, Animol Discovery. “Despite this strong demand, innovation is lagging. At Animol, we seek to address this innovation gap by leveraging the most advanced tools from human pharma to bring forward a wealth of new medicines that can benefit animals and the people who care for them.”
Founded in 2020 and incubated by Anterra Capital, Animol is pioneering the use of DNA Encoded Library (DEL) drug discovery technology coupled with powerful machine learning approaches to enable the rapid discovery of novel veterinary medicines.
“We have built Animol on the same cutting edge discovery techniques that we are using to disrupt drug discovery in human pharma (ZebiAI - acquired by Relay Therapeutics) and crop protection (Enko Chem),” said Philip Austin, Managing Partner at Anterra Capital. “Translating these tools to the massive opportunity available in veterinary pharma was the next obvious step and we are already seeing their use successfully build into a rich pipeline of promising compounds.”
Animol also announced that Marijn Dekkers PhD, founder & chairman of Novalis LifeSciences LLC will join the Board of Directors. Dr. Dekkers formerly served as the CEO of Bayer AG, and as the CEO of Thermo Fisher Scientific, Inc. At Bayer he oversaw one of the largest global animal health companies.
“Most current medicines in the $40B veterinary pharma market are derived from drugs that have been originally developed for humans. There is of course nothing wrong with that, but there are many animal-specific diseases that require a targeted effort. I like Animol Discovery’s approach to use its breakthrough drug discovery platform to specifically address significant unmet needs in animals. I am looking forward to working with the team to optimize the opportunity ahead,” said Dr. Dekkers.
“It is a great pleasure to be able to welcome Marijn Dekkers to our Board of Directors. Dr. Dekkers is an exceptional industry leader with a track record of turning innovation into successful businesses across the spectrum of life sciences, including in animal health,” said Andrew Plant PhD, chief executive officer, Animol Discovery. “He is an excellent addition to our team of experienced industry leaders.”
“I am also delighted to bring Doug Hutchens on board as chief scientific officer. Dr. Hutchens brings a wealth of industry experience in animal health research and product development; having someone who has also served as Chief Veterinary Officer within a major animal health company brings huge value to our expanding team,” added Dr. Plant.
“I am thrilled by the prospect of joining Animol’s dynamic and experienced team as chief scientific officer,” said Doug Hutchens, DVM, PhD. “The company’s ability to interrogate protein targets with billions of DNA-tagged molecules and, using DNA sequencing, identify selective inhibitors from numerous diverse chemical families is game changing in animal health drug discovery. Leveraging these data with proprietary, highly predictive machine learning algorithms, is enabling the identification of novel drug-like compounds in a matter of weeks from the initial DEL screen. This technology platform greatly expands the opportunities, significantly increases the probability, and accelerates the timeline in developing new classes of therapeutic molecules.”
About Animol
Animol is a pioneer in using state of the art drug discovery technology to discover small molecule active pharmaceutical ingredients to transform standards of care in veterinary medicine. The company is reducing the time and cost to discover novel active ingredients utilizing DNA-encoded libraries, machine learning/AI and structure-based design.
Animol is a private company based in Boston, Massachusetts. For more information see www.Animol-discovery.com
About Novalis LifeSciences LLC
Novalis LifeSciences LLC is an investment and advisory firm for the Life Science industry that was founded in 2017 by Marijn E. Dekkers. With a team of experienced operating executives from the Life Science industry, Novalis funds and advises visionary Life Science entrepreneurs. In addition to making financial investments, Novalis provides strategic and operational advice to portfolio companies that are at a critical growth stage in their development. For more information, visit www.novalislifesciences.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005186/en/
Contact information
Dr. Andrew Plant
CEO
Animol Discovery, Inc.
andrew.plant@animol-discovery.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enerin raises €15 million Series A to industrialise modular high-temperature heat pumps for global industry26.11.2025 11:00:00 EET | Press release
Enerin, a technology leader in high-temperature heat pumps, has raised €15 million (NOK 180 million) in a Series A led by Climentum Capital, The Footprint Firm, Johnson Controls and Move Energy, with participation from PSV Hafnium and Momentum. “This investment marks our shift from pioneering to full industrialisation, bringing proven high-temperature technology from Norway to industries worldwide,” said Arne Høeg, Founder and CEO of Enerin. “Industrial companies are ready to decarbonise high-temperature heat, but the mass market has lacked simple, profitable solutions that fit everyday operations.” Replacing fossil-fuelled industrial boilers — responsible for nearly 20% of global CO₂ emissions — remains one of the toughest challenges in the energy transition, largely because conventional heat pumps can’t cope with the sector’s highly variable process conditions and high temperatures. Enerin’s modular, flexible and standardised system removes such barriers by adapting automatically to
IQM to Invest Over €40 Million to Expand Finland Production Facility, Accelerate Innovation and Fuel Growth26.11.2025 10:49:00 EET | Press release
IQM Quantum Computers, a global leader in superconducting quantum computers, today announced over €40 million investment to expand its state-of-the-art production facility in Finland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126943986/en/ This strategic expansion will accelerate the development, fabrication and testing of advanced quantum processing units and the assembly of quantum computers, paving the way for scalable, error-corrected quantum systems that will power the next era of computing. The expansion aligns with the company’s recent Series B fundraise of over $300 million. The facility, which will spread over 8,000 square meters, will expand the company’s cleanroom area quantum data centre. It will also double its assembly line capacity, enabling to produce over 30 full-stack quantum computers per year, helping to meet the growing demand for its systems and support research innovation and development activi
Thredd Powers Successful Migration of BigPay’s Card Portfolio to Next-Gen Platform26.11.2025 10:00:00 EET | Press release
Thredd, the leading next-generation global payments processor, has successfully migrated BigPay’s virtual and physical card portfolio from its previous, legacy processor to Thredd’s next-generation platform, underscoring Thredd’s leadership in complex card portfolio migrations. The migration project, one of several in recent years, included over 2.5 million cards and highlights Thredd’s unique combination of deep migration experience, robust processes, and advanced technology—qualities increasingly critical as the industry faces a wave of modernisation and replatforming. This achievement comes at a pivotal moment for the industry. Industry analysts estimate that retail banks failing to modernise could see 10% to 15% of their payments revenue at risk annually as legacy platforms struggle to keep pace with demands for hyperpersonalization, digital experiences, faster time-to-market, and operational efficiencies. With more than 100 million cards per year expected to move to modern platfor
With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?26.11.2025 09:00:00 EET | Press release
An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (39%) leaving or considering leaving their roles while undergoing treatment.1 ‘The Impact of Fertility Challenges at Work: International Insights’ survey by Ferring Pharmaceuticals, Fertility Matters at Work and This Can Happen shows that, despite growing awareness of reproductive health, two thirds (67%) who have experienced fertility challenges say that their workplaces do not offer support for employees undergoing fertility treatment, with France the least likely to provide it (88%).1 60% said they were not clearly entitled to time off for fertility appointments, with time recorded as paid leave, unpaid leave or annual leave (26%), and some also reported taking sick leave due to a lack of flexibility (17%).1 With assisted reproduction therapy, including IVF, already accounting for up to 1
Venture Global and Tokyo Gas Announce 20-Year LNG Sales and Purchase Agreement26.11.2025 02:00:00 EET | Press release
Today, Venture Global, Inc. (NYSE: VG) and Tokyo Gas Co., Ltd announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Tokyo Gas will procure 1 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. This deal marks 7.75MTPA of SPAs signed by Venture Global in the last six months. “With nearly 8 MTPA of new long-term commitments signed this year, Venture Global is pleased to build on our commercial momentum through this new partnership with Tokyo Gas,” said Venture Global CEO Mike Sabel. “Tokyo Gas is a pioneer in the LNG industry and leading provider of natural gas to Japan, and we look forward to working with them as we grow our position as a top LNG supplier to Japan. This agreement will contribute significantly to the US-Japan balance of trade over the duration of the SPA, providing Japan with affordable, reliable American LNG.” About Venture Global Venture Global is an American pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom